NVCR: FY25 Deep Dive
FY25 revenue $655M; OI $-154M; NI $-136M; EPS $-1.22.
NovoCure FY25 (Dec 31, 2025) at $655M revenue. OpInc $-154M; NI $-136M; EPS $-1.22. Medical Devices — Oncology.
NovoCure FY25 at $655M. NI $-136M; EPS $-1.22.
FY25 revenue $655M; OI $-154M; NI $-136M; EPS $-1.22.
NovoCure FY25 (Dec 31, 2025) at $655M revenue. OpInc $-154M; NI $-136M; EPS $-1.22. Medical Devices — Oncology.
Want deeper analysis?
Ask drillr anything about NVCR — powered by SEC filings, earnings calls, and real-time data.
Try drillr.ai for free